APA (7th ed.) Citation

T, R., H, H., J, J., J, Z., T, L., O, S., . . . F, C. (2019). Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study. Leukemia & lymphoma, 60(1), 172. https://doi.org/10.1080/10428194.2017.1321750

Chicago Style (17th ed.) Citation

T, Robak, et al. "Association Between Bortezomib Dose Intensity and Overall Survival in Mantle Cell Lymphoma Patients on Frontline VR-CAP in the Phase 3 LYM-3002 Study." Leukemia & Lymphoma 60, no. 1 (2019): 172. https://doi.org/10.1080/10428194.2017.1321750.

MLA (9th ed.) Citation

T, Robak, et al. "Association Between Bortezomib Dose Intensity and Overall Survival in Mantle Cell Lymphoma Patients on Frontline VR-CAP in the Phase 3 LYM-3002 Study." Leukemia & Lymphoma, vol. 60, no. 1, 2019, p. 172, https://doi.org/10.1080/10428194.2017.1321750.